Nilotinib
NSCLC
Convalife (Shanghai) Co., Ltd.Small moleculePhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 65/ 100
Competitive context
111 Active assets in the NSCLC cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dacomitinib Pfizer | Phase 4 | BB |
Penpulimab Yang Fan, MD | Phase 4 | BB |
Fruquintinib Immunitas Therapeutics | Phase 3 | BB |
Adebrelimab Peking University Cancer Hospital & Institute | Phase 3 | BB |
Rezivertinib The First Affiliated Hospital of Guangzhou Medical University | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Nilotinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
74 / 100
View asset →blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
70 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →